Sphera Funds Management LTD. acquired a new position in Zogenix, Inc. (NASDAQ:ZGNX) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $1,085,000.
A number of other large investors have also modified their holdings of the company. American International Group Inc. boosted its stake in shares of Zogenix by 7.1% in the first quarter. American International Group Inc. now owns 15,278 shares of the company’s stock worth $166,000 after buying an additional 1,010 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Zogenix by 29.5% in the first quarter. Nationwide Fund Advisors now owns 18,748 shares of the company’s stock worth $203,000 after buying an additional 4,266 shares in the last quarter. Bank of New York Mellon Corp raised its position in Zogenix by 4.6% in the first quarter. Bank of New York Mellon Corp now owns 103,459 shares of the company’s stock worth $1,123,000 after buying an additional 4,583 shares in the last quarter. A.R.T. Advisors LLC purchased a new position in Zogenix during the fourth quarter worth $154,000. Finally, Acadian Asset Management LLC purchased a new position in Zogenix during the first quarter worth $172,000. Hedge funds and other institutional investors own 87.10% of the company’s stock.
Shares of Zogenix, Inc. (NASDAQ:ZGNX) traded up 1.39% during trading on Friday, reaching $14.60. 580,405 shares of the company traded hands. Zogenix, Inc. has a 12-month low of $7.33 and a 12-month high of $15.20. The company has a 50 day moving average price of $12.98 and a 200 day moving average price of $11.29. The firm’s market capitalization is $362.27 million.
Zogenix (NASDAQ:ZGNX) last posted its earnings results on Thursday, May 4th. The company reported ($0.85) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.88) by $0.03. Zogenix had a negative net margin of 360.89% and a negative return on equity of 57.74%. The firm had revenue of $2.70 million for the quarter, compared to analyst estimates of $4.23 million. During the same period in the previous year, the firm posted ($0.42) EPS. The company’s revenue for the quarter was down 70.7% compared to the same quarter last year. On average, equities analysts predict that Zogenix, Inc. will post ($3.63) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/06/16/sphera-funds-management-ltd-buys-new-position-in-zogenix-inc-zgnx-updated-updated.html.
A number of research analysts have weighed in on ZGNX shares. Zacks Investment Research lowered shares of Zogenix from a “buy” rating to a “hold” rating in a research report on Wednesday, March 15th. Aegis reaffirmed a “buy” rating and set a $28.00 price objective on shares of Zogenix in a research note on Saturday, March 11th.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.